Using RNA to interfere with a gene’s expression of disease-causing proteins is a validated therapeutic approach, but so far, the products in this drug class only address liver proteins. Reducing ...

A "gene silencer" (technically known as small interfering RNA, or siRNA), locally delivered by nanoparticles embedded in an ...

Discover how a newly developed platform technology from The University of North Carolina at Chapel Hill can enhance RNAi ...

The discovery of siRNA and its role in RNAi was a groundbreaking finding in the field of molecular biology. In 1998, Andrew Fire and Craig Mello published a seminal paper describing the phenomenon of ...

(A and B) Preparation process of the self-assembly of peptide, DNR prodrug, and siRNA, along with the corresponding formulation ratios. (C) DLS detection of the particle size of PDR at different ...

A new possibility for managing cardiovascular disease through RNA interference (RNAi) gene therapies. As cardiovascular diseases continue to be the leading cause of death globally, this technology ...

Explore RNA interference methods, comparing siRNA and shRNA for gene knockdown, their mechanisms, advantages, and ...

Nearly 1.3 billion adults around the world have clinically high blood pressure, many of whom may be unaware that they are living with this condition. Nearly 1.3 billion adults around the world have ...

An experimental RNA therapy from Avidity Biosciences has early clinical trial results showing it reduced by half the expression of a gene at the root of a rare, inherited form of muscular dystrophy ...

Collaboration focuses on developing potential best in class siRNA-based treatment for a form of dilated cardiomyopathy Bayer to further strengthen cardiovascular portfolio and enter dynamic field of ...